Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Winner Medical Co., Ltd., a subsidiary of Winner Group Limited, is a company dedicated to the entire lifecycle – from innovation and production to sales – of cotton-derived medical supplies and various consumer goods. Based in Shenzhen, China, its business primarily serves the Chinese market, yet its products reach customers in approximately 110 countries globally. The company's operations are distinctly segmented into Medical Consumables and Healthy Consumer Goods. Under the Medical Consumables umbrella, Winner Medical offers a comprehensive selection of wound care items, which include various gauze and non-woven dressings, bandages, complete dressing change kits, and advanced options like silicone and alginate dressings. This division also produces essential infection control products such as surgical kits, protective gowns, face masks, full-body protective clothing, isolation garments, gloves, and specialized footwear and headwear. Moreover, it supplies a range of disinfection and cleaning products, from cotton swabs, pads, and balls to alcohol wipes and general disinfectants. The Healthy Consumer Goods segment features its own line of non-woven fabric, alongside a broad array of finished non-woven consumer items like cotton facial tissues, wet wipes, feminine hygiene products, cotton buds, cosmetic pads, and disposable undergarments. This segment further extends to textile consumer products, offering everything from baby essentials and clothing to adult apparel and other fabric-based goods. These diverse product lines are marketed under the distinct brand names "Winner," "Purcotton," and "PureH2B." The company utilizes a multi-channel distribution strategy, engaging with pharmacy chains, hospitals, e-commerce platforms, and supermarkets to deliver its products. Winner Medical Co., Ltd. was founded in 1991.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EB
Target Price
The average target price of 300888.SZ is 41.4 and suggests 49.5% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to